Meet the Lawyer Leading the Human Resistance Against AI
https://www.wired.com/story/matthew-butterick-ai-copyright-lawsuits-openai-meta/
Nov 22, 2023 - Matthew Butterick is leading a wave of lawsuits against major AI firms, from OpenAI to Meta. Win or lose, his work will shape the future of human creativity.
0
Roche (RHHBY) Breast Cancer Drug Meets Primary Goal in Phase III
https://www.zacks.com/stock/news/2193809/roche-rhhby-breast-cancer-drug-meets-primary-goal-in-phase-iii?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193809
Dec 05, 2023 - Roche's (RHHBY) phase III study evaluating inavolisib in combination with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation achieves its primary goal.
0
Pharvaris (PHVS) Stock Up 18% on HAE Drug Meeting Study Goal
https://www.zacks.com/stock/news/2195115/pharvaris-phvs-stock-up-18-on-hae-drug-meeting-study-goal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2195115
Dec 07, 2023 - Data from a mid-stage study shows that treatment with Pharvaris' (PHVS) investigational HAE drug reduced the monthly attack rate by 84.5%.
0
November CPI/Core CPI Meet Expectations
https://www.zacks.com/stock/news/2196845/november-cpi-core-cpi-meet-expectations?cid=CS-ZC-FT-economic_highlights-2196845
Dec 12, 2023 - November CPI/Core CPI Meet Expectations.
0
Delta (DAL) Adds Houston Flights to Meet Football Frenzy
https://www.zacks.com/stock/news/2205083/delta-dal-adds-houston-flights-to-meet-football-frenzy?cid=CS-ZC-FT-analyst_blog|company_news_-_corporate_actions-2205083
Jan 03, 2024 - Delta (DAL) new flights are set to have 1,272 additional seats for football fans heading to Houston.
0
Alphabet (GOOGL) Boosts Google Meet Offerings With "Calls" Tab
https://www.zacks.com/stock/news/2206379/alphabet-googl-boosts-google-meet-offerings-with-calls-tab?cid=CS-ZC-FT-analyst_blog|company_news_tech_sector-2206379
Jan 05, 2024 - Alphabet (GOOGL) adds a "Calls" tab to its Google Meet web app, bolstering its Workspace offerings.
0
Novo Nordisk's (NVO) Phase III Diabetes Study Meets Primary Goal
https://www.zacks.com/stock/news/2207561/novo-nordisk-s-nvo-phase-iii-diabetes-study-meets-primary-goal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2207561
Jan 09, 2024 - Novo Nordisk (NVO) reports positive top-line data from one of its late-stage studies under the COMBINE program evaluating once-weekly IcoSema in type II diabetes patients.
0
U.S. Bancorp's (USB) Q4 Earnings Meet Estimates, Costs Up
https://www.zacks.com/stock/news/2211682/u-s-bancorp-s-usb-q4-earnings-meet-estimates-costs-up?cid=CS-ZC-FT-analyst_blog|earnings_article-2211682
Jan 17, 2024 - U.S. Bancorp's (USB) Q4 earnings gain from a rise in revenues and an improvement in credit quality. However, higher expenses and lower NII act as headwinds.
0
Prologis (PLD) Q4 FFO Meet Estimates
https://www.zacks.com/stock/news/2211376/prologis-pld-q4-ffo-meet-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2211376
Jan 17, 2024 - Prologis (PLD) delivered FFO and revenue surprises of 0% and 1.62%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
0
U.S. Bancorp (USB) Q4 Earnings Meet on Higher Fee Income
https://www.zacks.com/stock/news/2212226/u-s-bancorp-usb-q4-earnings-meet-on-higher-fee-income?cid=CS-ZC-FT-analyst_blog|earnings_article-2212226
Jan 18, 2024 - U.S. Bancorp (USB) meets Q4 earnings estimates on higher fee income and lower provision for credit losses compared with the year-ago quarter.
0